Department of Cardiology, Ospedali del Tigullio, Lavagna, GE, Italy.
Department of Cardiology, Arcispedale S. Maria Nuova, Reggio Emilia, Italy.
Int J Cardiol. 2019 Aug 15;289:70-73. doi: 10.1016/j.ijcard.2019.03.043. Epub 2019 Mar 22.
Patients affected by syncope without or with very short (≤5 s) prodrome with normal heart and normal ECG have been seen to present low plasma adenosine levels. We investigated whether chronic treatment of these patients with theophylline, a non-selective adenosine receptor antagonist, results in clinical benefit.
In a consecutive case-series of 16 patients (mean age 47 ± 25 years, 9 females) who had ECG documentation of asystolic syncope, we compared the incidence of syncopal recurrence during a period without and a period with tailored theophylline therapy.
During a median of 60 months before ECG documentation of the index episode, the patients had a median of 2 syncopes per year. During the 6 months of the study phase without therapy, the patients had a median of 2.6 syncopes per year, p = 0.63. During the 23 months of the study phase with theophylline, the patients had a median of 0.4 syncopes per year, p = 0.005 vs history and p = 0.005 vs no therapy. In the 13 patients who had an implantable loop recorder during both study phases, the incidence of asystolic episodes > 3 s decreased from 9.6 per year to 1.1 per year, p = 0.0007. During theophylline treatment, syncope recurred in 1/5 (20%) patients who had an idiopathic atrioventricular block as the index event versus 9/11 (81%) patients who had a sinus arrest, p = 0.005.
Theophylline is effective in reducing syncopal burden in patients with syncope without prodromes with normal heart and normal ECG. Its efficacy is greater in those with idiopathic atrioventricular block.
伴有或不伴有极短(≤5s)前驱期且心脏和心电图正常的晕厥患者,其血浆腺苷水平较低。我们研究了这些患者接受茶碱(一种非选择性腺苷受体拮抗剂)长期治疗是否会带来临床获益。
我们连续纳入了 16 名(平均年龄 47±25 岁,9 名女性)心电图记录为停搏性晕厥的患者,比较了在未接受和接受个体化茶碱治疗期间的晕厥复发发生率。
在首次晕厥发作的心电图记录之前的中位 60 个月期间,患者每年的晕厥发作中位数为 2 次。在未接受治疗的研究阶段的 6 个月期间,患者每年的晕厥发作中位数为 2.6 次,p=0.63。在接受茶碱治疗的 23 个月期间,患者每年的晕厥发作中位数为 0.4 次,p=0.005(与病史相比)和 p=0.005(与未治疗相比)。在 13 名在两个研究阶段均植入植入式环路记录器的患者中,>3s 的停搏发作次数从每年 9.6 次减少至每年 1.1 次,p=0.0007。在茶碱治疗期间,有 1/5(20%)以特发性房室阻滞为首发事件的患者出现晕厥复发,而有 9/11(81%)以窦性停搏为首发事件的患者出现晕厥复发,p=0.005。
茶碱可有效降低心脏和心电图正常的无前驱期晕厥患者的晕厥负担。其疗效在特发性房室阻滞患者中更大。